Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?

C. Dazzi, A. Cariello, G. Rosti, M. Argnani, L. Sebastiani, E. Ferrari, L. Zornetta, G. Monti, P. Nicoletti, M. Baioni, M. Salvucci, E. Scarpi, M. Marangolo

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m 2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 μg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of CD34+ cells considered as the target for each high-dose chemotherapy was ≥ 2 × 10 6 /Kg/bw. Fifteen leukaphereses procedures were necessary in group A, while 16 procedures were performed in group B. We did not observe any difference between the two groups in terms of CD34+ cells/μl in the peripheral blood (117 vs 78; p=NS), whereas in the aphereses product we found a significant difference between the two groups of patients in terms of CD34+ cells (6.41 vs 2.89 × 10 6/Kg/bw; p=.009), CFU-GM (82.5 vs 52.3 × 10 4/Kg/bw; p=.04). Interestingly, we noted a different distribution of CD34+/33- cells between the 2 groups (mean value 39% vs 65%; p

Original languageEnglish
Pages (from-to)301-310
Number of pages10
JournalLeukemia and Lymphoma
Volume39
Issue number3-4
Publication statusPublished - 2000

Fingerprint

Granulocyte Colony-Stimulating Factor
Non-Hodgkin's Lymphoma
Cyclophosphamide
Cell Count
Leukapheresis
Granulocyte-Macrophage Progenitor Cells
Blood Component Removal
Intercellular Signaling Peptides and Proteins
Stem Cells
Drug Therapy

Keywords

  • Engraftment kinetics
  • G-CSF
  • High dose cyclophosphamide
  • Non-Hodgkin lymphoma
  • PBPC mobilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Dazzi, C., Cariello, A., Rosti, G., Argnani, M., Sebastiani, L., Ferrari, E., ... Marangolo, M. (2000). Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma? Leukemia and Lymphoma, 39(3-4), 301-310.

Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma? / Dazzi, C.; Cariello, A.; Rosti, G.; Argnani, M.; Sebastiani, L.; Ferrari, E.; Zornetta, L.; Monti, G.; Nicoletti, P.; Baioni, M.; Salvucci, M.; Scarpi, E.; Marangolo, M.

In: Leukemia and Lymphoma, Vol. 39, No. 3-4, 2000, p. 301-310.

Research output: Contribution to journalArticle

Dazzi, C, Cariello, A, Rosti, G, Argnani, M, Sebastiani, L, Ferrari, E, Zornetta, L, Monti, G, Nicoletti, P, Baioni, M, Salvucci, M, Scarpi, E & Marangolo, M 2000, 'Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?', Leukemia and Lymphoma, vol. 39, no. 3-4, pp. 301-310.
Dazzi, C. ; Cariello, A. ; Rosti, G. ; Argnani, M. ; Sebastiani, L. ; Ferrari, E. ; Zornetta, L. ; Monti, G. ; Nicoletti, P. ; Baioni, M. ; Salvucci, M. ; Scarpi, E. ; Marangolo, M. / Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?. In: Leukemia and Lymphoma. 2000 ; Vol. 39, No. 3-4. pp. 301-310.
@article{e96f86059aca437b802798d12053fb93,
title = "Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?",
abstract = "We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m 2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 μg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of CD34+ cells considered as the target for each high-dose chemotherapy was ≥ 2 × 10 6 /Kg/bw. Fifteen leukaphereses procedures were necessary in group A, while 16 procedures were performed in group B. We did not observe any difference between the two groups in terms of CD34+ cells/μl in the peripheral blood (117 vs 78; p=NS), whereas in the aphereses product we found a significant difference between the two groups of patients in terms of CD34+ cells (6.41 vs 2.89 × 10 6/Kg/bw; p=.009), CFU-GM (82.5 vs 52.3 × 10 4/Kg/bw; p=.04). Interestingly, we noted a different distribution of CD34+/33- cells between the 2 groups (mean value 39{\%} vs 65{\%}; p",
keywords = "Engraftment kinetics, G-CSF, High dose cyclophosphamide, Non-Hodgkin lymphoma, PBPC mobilization",
author = "C. Dazzi and A. Cariello and G. Rosti and M. Argnani and L. Sebastiani and E. Ferrari and L. Zornetta and G. Monti and P. Nicoletti and M. Baioni and M. Salvucci and E. Scarpi and M. Marangolo",
year = "2000",
language = "English",
volume = "39",
pages = "301--310",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "3-4",

}

TY - JOUR

T1 - Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?

AU - Dazzi, C.

AU - Cariello, A.

AU - Rosti, G.

AU - Argnani, M.

AU - Sebastiani, L.

AU - Ferrari, E.

AU - Zornetta, L.

AU - Monti, G.

AU - Nicoletti, P.

AU - Baioni, M.

AU - Salvucci, M.

AU - Scarpi, E.

AU - Marangolo, M.

PY - 2000

Y1 - 2000

N2 - We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m 2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 μg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of CD34+ cells considered as the target for each high-dose chemotherapy was ≥ 2 × 10 6 /Kg/bw. Fifteen leukaphereses procedures were necessary in group A, while 16 procedures were performed in group B. We did not observe any difference between the two groups in terms of CD34+ cells/μl in the peripheral blood (117 vs 78; p=NS), whereas in the aphereses product we found a significant difference between the two groups of patients in terms of CD34+ cells (6.41 vs 2.89 × 10 6/Kg/bw; p=.009), CFU-GM (82.5 vs 52.3 × 10 4/Kg/bw; p=.04). Interestingly, we noted a different distribution of CD34+/33- cells between the 2 groups (mean value 39% vs 65%; p

AB - We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m 2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 μg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of CD34+ cells considered as the target for each high-dose chemotherapy was ≥ 2 × 10 6 /Kg/bw. Fifteen leukaphereses procedures were necessary in group A, while 16 procedures were performed in group B. We did not observe any difference between the two groups in terms of CD34+ cells/μl in the peripheral blood (117 vs 78; p=NS), whereas in the aphereses product we found a significant difference between the two groups of patients in terms of CD34+ cells (6.41 vs 2.89 × 10 6/Kg/bw; p=.009), CFU-GM (82.5 vs 52.3 × 10 4/Kg/bw; p=.04). Interestingly, we noted a different distribution of CD34+/33- cells between the 2 groups (mean value 39% vs 65%; p

KW - Engraftment kinetics

KW - G-CSF

KW - High dose cyclophosphamide

KW - Non-Hodgkin lymphoma

KW - PBPC mobilization

UR - http://www.scopus.com/inward/record.url?scp=0034485697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034485697&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 301

EP - 310

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -